Multiple Myeloma
📧 Sign up to get email alerts when something new happens for Multiple Myeloma.
Sign up freeTop drugs studied for this disease
-
CLINICAL_TRIALS research · 2026-04-14Clinical Trial Update: FT836 CAR T-cell Therapy in Combination With Daratumumab in Patients With Relapsed and/or Refractory Multiple Myeloma [Phase 1]
Phase 1 clinical trial evaluating FT836 CAR T-cell therapy in combination with daratumumab for relapsed or refractory multiple myeloma; stat…
-
CLINICAL_TRIALS research · 2026-04-14Clinical Trial Update: A Phase 2 Study of Radiotherapy-induced Immune Priming to Enhance Elranatamab (Elra) in Relapsed Refractory Multiple Myeloma (RRMM) With Extramedullary Disease (EMD) and Paramedullary Disease (PMD) "PRIME-EMD-PMD" [Phase 2]
This is a Phase 2 trial evaluating radiotherapy-induced immune priming to enhance Elranatamab in relapsed/refractory multiple myeloma with e…
-
CLINICAL_TRIALS trial_result · 2026-04-14Clinical Trial Update: A Study to Assess Safety of Teclistamab in Indian Participants With Relapsed and Refractory Multiple Myeloma [Phase 4]
Clinical trial update shows a Phase 4 study to assess safety of Teclistamab in Indian participants with relapsed and refractory multiple mye…
-
CLINICAL_TRIALS research · 2026-04-14Clinical Trial Update: A Study to Evaluate Adverse Events, Change in Disease Activity, Tolerability, and How Intravenous ABBV-438 Moves Through the Body in Adult Participants With Multiple Myeloma (MM) [Phase 1]
Phase 1 trial update evaluating adverse events, changes in disease activity, tolerability, and pharmacokinetics of intravenous ABBV-438 in a…
-
CLINICAL_TRIALS research · 2026-04-14Clinical Trial Update: Collection of Tissue Samples for Cancer Research
This recruiting trial aims to collect tissue samples for cancer research, sponsored by the National Cancer Institute. It encompasses neoplas…
- Want full summaries, importance scores, and drug timelines? Upgrade to Plus or Pro.
-
CLINICAL_TRIALS research · 2026-04-14Clinical Trial Update: Study to Assess Safety and Efficacy of HDP-101 in Chinese Patients With Relapsed or Refractory Multiple Myeloma [Phase 1]
A Phase 1 trial to assess safety and efficacy of HDP-101 in Chinese patients with relapsed or refractory multiple myeloma, currently recruit…
-
CLINICAL_TRIALS research · 2026-04-13Clinical Trial Update: A Study to Evaluate Efficacy, Safety, and PK of XEMBIFY®+Standard Medical Treatment (SMT) Compared to Placebo+SMT to Prevent Infections in Participants With HGG and Recurrent or Severe Infections Associated With B-cell Chronic Lymphocytic Leukemia, Multiple Myeloma, and Non-Hodgkin Lymphoma [Phase 3]
A Phase 3 clinical trial is evaluating the efficacy, safety, and pharmacokinetics of XEMBIFY plus standard medical treatment (SMT) versus pl…
-
CLINICAL_TRIALS research · 2026-04-13Clinical Trial Update: A Study of Bortezomib, Lenalidomide and Dexamethasone (VRd) Followed by Cilta-cel, a CAR-T Therapy Directed Against BCMA Versus VRd Followed by Lenalidomide and Dexamethasone (Rd) Therapy in Participants With Newly Diagnosed Multiple Myeloma for Whom ASCT is Not Planned as Initial Therapy [Phase 3]
Phase 3 study comparing VRd induction followed by cilta-cabtagene autoleucel (cilta-cel) CAR-T therapy versus Rd therapy in newly diagnosed …
-
CLINICAL_TRIALS trial_result · 2026-04-13Clinical Trial Update: Analysis of Effectiveness and Safety of Teclistamab in Relapsed and Refractory Multiple Myeloma Patients
An update reporting on the analysis of effectiveness and safety of teclistamab in patients with relapsed and refractory multiple myeloma in …
-
CLINICAL_TRIALS research · 2026-04-13Clinical Trial Update: A Study Comparing Teclistamab Monotherapy Versus Pomalidomide, Bortezomib, Dexamethasone (PVd) or Carfilzomib, Dexamethasone (Kd) in Participants With Relapsed or Refractory Multiple Myeloma [Phase 3]
A Phase 3 trial evaluating teclistamab monotherapy against PVd or Kd in relapsed or refractory multiple myeloma; study status is active but …
-
CLINICAL_TRIALS trial_result · 2026-04-13Clinical Trial Update: A Study Evaluating the Safety and Pharmacokinetics of Escalating Doses of Forimtamig in Participants With Relapsed or Refractory Multiple Myeloma (r/r MM) [Phase 1]
The document reports the completed Phase 1 study evaluating escalating doses of the investigational drug forimtamig in relapsed or refractor…
-
CLINICAL_TRIALS research · 2026-04-13Clinical Trial Update: A Study Comparing JNJ-79635322 and an Anti-B-cell Maturation Antigen (BCMA)xCD3 Bispecific Antibody in Participants With Relapsed or Refractory Multiple Myeloma [Phase 3]
A Phase 3 clinical trial comparing JNJ-79635322 with an anti-BCMAxCD3 bispecific antibody in relapsed or refractory multiple myeloma is curr…
-
CLINICAL_TRIALS trial_result · 2026-04-13Clinical Trial Update: Mezigdomide and Talquetamab in Relapsed and Refractory Multiple Myeloma [Phase 1]
A Phase 1 study is evaluating the combination of mezigdomide and talquetamab in relapsed and refractory multiple myeloma and is currently re…
-
CLINICAL_TRIALS research · 2026-04-13Clinical Trial Update: A Clinical Trial of Four Medicines (Elranatamab Plus Carfilzomib and Dexamethasone or Maplirpacept) in People With Relapsed Refractory Multiple Myeloma [Phase 1]
A Phase 1 clinical trial update describing a study of four medicines (Elranatamab plus carfilzomib and dexamethasone or Maplirpacept) in adu…
-
CLINICAL_TRIALS research · 2026-04-13Clinical Trial Update: A Study of Teclistamab in Combination With Daratumumab and Lenalidomide (Tec-DR) and Talquetamab in Combination With Daratumumab and Lenalidomide (Tal-DR) in Participants With Newly Diagnosed Multiple Myeloma [Phase 3]
Phase 3 clinical trial update evaluating Teclistamab in combination with Daratumumab and Lenalidomide (Tec-DR) and Talquetamab in combinatio…
-
CLINICAL_TRIALS research · 2026-04-13Clinical Trial Update: CB-839 HCl in Combination With Carfilzomib and Dexamethasone in Treating Patients With Recurrent or Refractory Multiple Myeloma [Phase 1]
This document reports a Phase 1 clinical trial update on the combination of telaglenastat (CB-839) with carfilzomib and dexamethasone for pa…
-
CLINICAL_TRIALS research · 2026-04-13Clinical Trial Update: Measurable Residual Disease-Guided Post-Transplant Elranatamab Maintenance [Phase 2]
A Phase 2 trial evaluating measurable residual disease-guided post-transplant maintenance with elranatamab for multiple myeloma. The study i…
-
CLINICAL_TRIALS research · 2026-04-13Clinical Trial Update: Testing the Investigational Medication Combination of Teclistamab and Pomalidomide Compared to the Usual Treatment (Carfilzomib, Pomalidomide, and Dexamethasone) for Patients With Multiple Myeloma Who Have Relapsed Shortly After Treatment [Phase 1, Phase 2]
A Phase 1/2 clinical trial comparing Teclistamab plus Pomalidomide against the standard Carfilzomib-Pomalidomide-Dexamethasone in patients w…
-
CLINICAL_TRIALS research · 2026-04-13Clinical Trial Update: A Study of Subcutaneous Daratumumab Regimens in Combination With Bispecific T Cell Redirection Antibodies for the Treatment of Participants With Multiple Myeloma [Phase 1]
This clinical trial update describes a Phase 1 study evaluating subcutaneous daratumumab regimens in combination with bispecific T cell redi…
-
CLINICAL_TRIALS research · 2026-04-13Clinical Trial Update: Remote Monitoring With Health-Coaching to Improve Quality of Life in Older Patients With Multiple Myeloma [NA]
This trial update covers a Mayo Clinic study evaluating remote monitoring with health coaching to improve quality of life in older adults wi…
-
CLINICAL_TRIALS research · 2026-04-13Clinical Trial Update: A Study of Different Sequences of Cilta-cel, Talquetamab in Combination With Daratumumab and Teclistamab in Combination With Daratumumab Following Induction With Daratumumab, Bortezomib, Lenalidomide and Dexamethasone in Participants With Standard-risk Newly Diagnosed Multiple Myeloma [Phase 2]
Phase 2 clinical trial update evaluating sequences of cilta-cabtagene autoleucel and talquetamab in combination with daratumumab, and teclis…
-
CLINICAL_TRIALS research · 2026-04-13Clinical Trial Update: A Study to Evaluate Efficacy and Safety of Ciltacabtagene Autoleucel [Phase 2]
Ongoing Phase 2 clinical trial evaluating ciltacabtagene autoleucel (Carvykti) for multiple myeloma; the study is currently recruiting.
-
CLINICAL_TRIALS research · 2026-04-13Clinical Trial Update: A Study to Evaluate Preventive Treatments for GPRC5D-related Oral Events [Phase 2]
A Phase 2 clinical trial is evaluating preventive treatments for GPRC5D-related oral events in patients with multiple myeloma, and the study…
-
CLINICAL_TRIALS trial_result · 2026-04-13Clinical Trial Update: Connect® MM- The Multiple Myeloma Disease Registry
The Connect MM registry trial for multiple myeloma sponsored by Celgene has been terminated.
-
CLINICAL_TRIALS trial_result · 2026-04-13Clinical Trial Update: A Study of Teclistamab in Participants With Relapsed or Refractory Multiple Myeloma [Phase 2]
Teclistamab is being studied in a Phase 2 trial for relapsed or refractory multiple myeloma. The study status is active but not recruiting.